Latest News

Conferences

Events


Scientists from Synectix will be presenting at the following conferences worldwide. If you would like to arrange a meeting with us during the event, please contact us directly.

Nov 16-20, 2008
AAPS Annual Meeting and Exposition, Georgia World Congress Center Atlanta, GA

Dec 10-12, 2008
DDL19 - Drug Delivery to the Lungs, Edinburgh International Conference Centre

May 19-22, 2009
RDD Europe 2009,
Corinthia Lisboa Hotel, Lisbon, Portugal

July 18-22, 2009
Controlled Release Society, Copenhagen, Denmark

[Syn+ec+tics]:- an approach to solving problems based on the creative thinking of a group of people from different areas of expertise and knowledge......


At Synectix Pharmaceutical Solutions Ltd, we develop 'new generation' pharmaceutical and biopharmaceutical products using our proprietary drug formulation technologies, which are specifically applied to enhance the delivery and performance of poorly soluble and hydrophobic new chemical entities (NCEs) and commercial compounds showing poor bioavailability, as well as rescuing potential R&D drop-outs.

Our core research efforts are focused on the application of novel particle processing and 'drug activation' technologies to produce stable soluble intermediates for liquid, solid and semi-solid dosage forms. Using these bespoke technologies, we turn problematic and hard to develop drug candidates into easy to administer, stable and successful pharmaceutical products.

Our drug delivery technologies for solubility / bioavailability enhancement include:

SOLENT ARRAY

SOLENT™ ARRAY
High-throughput preclinical formulation screening platform for solubility enhancment of hydrophobic / lipophilic APIs
Learn more >>>
LENA NANOCEUTICS

LENA™ NANOCEUTICS
Crystalline nanoparticulate suspensions and dry powder formulations for dissolution velocity enhancement of hydrophobic APIs
Learn more >>>

PRORELEASE™ ASD

PRORELEASE™ ASD
Stabilised amorphous solid solution intermediates for bioavailability enhancement of low solubility, hydrophobic APIs
Learn more >>>

SOLENT-BIO


Case Studies


CASE STUDY 1:
Lead optimisation: rapid solubility and formulation screening for efficacy and PK studies
Learn more >>>


CASE STUDY 2:
Parenteral dosage form screening and development of a highly insoluble molecule
Learn more >>>


CASE STUDY 3:
Development of a fast dissolving nanoparticulate dry powder formulation for dissolution enhancement of a hydrophobic API
Learn more >>>


CASE STUDY 4:
Lyophilized parenteral formulation development of a poorly soluble biological
API
Learn more >>>


CASE STUDY 5:
Developement of an improved solubility stabilised amorphous solid solution intermediate to support 'first in man' clinical trials
Learn more >>>